Physician profile
Thomas B Gore
NPI 1639164874
$1,841.83
in general payments reported to CMS, 2019-2025
24 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $28.35 · 2021: $42.28 · 2022: $613 · 2023: $388 · 2024: $151 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $276.56 | 2022-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $207.32 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $190.32 | 2019-2025 | |
| Pfizer INC. | $143.17 | 2019-2023 | |
| Cvrx, INC. | $136.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.57 | 2022-2025 | Jardiance |
| Abbott Laboratories | $105.25 | 2022 | |
| Intuitive Surgical, INC. | $104.69 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.35 | 2019-2025 | Lifevest |
| Abiomed | $83.04 | 2023 | Impella |
| Merck Sharp & Dohme LLC | $48.05 | 2022 | |
| Boston Scientific Corporation | $43.18 | 2019-2025 | General - Therapies |
| Scpharmaceuticals INC. | $43.08 | 2025 | |
| Medtronic Vascular, INC. | $39.00 | 2019 | |
| Angiodynamics, INC. | $32.22 | 2023 | Alphavac |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $26.71 | 2025 | Flowtriever |
| Inari Medical, INC. | $24.80 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kestra Medical Technology Services, INC. | $23.95 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $20.23 | 2023 | Andexxa |
| Novo Nordisk INC | $19.15 | 2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $18.15 | 2024 | |
| Daiichi Sankyo INC. | $18.09 | 2023 | Injectafer |
| Gilead Sciences, INC. | $17.79 | 2019 | |
| Medtronic, INC. | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.